Citius Oncology, Inc. (CTOR) Key Metrics
CTOR valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $81.2M
- Enterprise value
- $100.5M
- P/E (TTM)
- —
- Forward P/E
- 10.1
- PEG ratio
- —
- Price / sales
- 11.4
- Price / book
- 2.6
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 3.40
CTOR key metrics, FY2021–FY2025
Fiscal year ended September 30, 2025 · U.S. dollarsCTOR valuation Price multiples at each fiscal year-end price.
CTOR returns How much profit the business earns on the capital it uses.
CTOR per-share figures Results divided by the shares outstanding at year-end.
CTOR financial health Debt, liquidity and how easily interest is covered.
CTOR valuation history
CTOR returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
CTOR debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
CTOR price vs earnings per share
CTOR key metrics
FY2021–FY2025| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Valuation | |||||
| Market capitalization | $148.7M | $99.5M | — | — | — |
| Enterprise value | $148.6M | $103.3M | — | — | — |
| Price / book | 3.3 | 2.2 | — | — | — |
| Price / free cash flow | — | 787.2 | — | — | — |
| Price / operating cash flow | — | 787.1 | — | — | — |
| EV / free cash flow | — | 817.2 | — | — | — |
| Earnings yield | −16.6% | −21.3% | — | — | — |
| Free cash flow yield | −3.7% | 0.1% | — | — | — |
| Share price at fiscal year-end | $2.03 | $1.39 | — | — | — |
| Per share | |||||
| Revenue per share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Earnings per share | −$0.34 | −$0.30 | −$0.14 | −$0.12 | −$0.00 |
| Operating cash flow per share | −$0.07 | $0.00 | −$0.01 | −$0.00 | — |
| Free cash flow per share | −$0.07 | $0.00 | −$0.01 | −$0.00 | — |
| Cash per share | $0.05 | $0.00 | $0.00 | $0.00 | — |
| Book value per share | $0.61 | $0.64 | $0.29 | $0.40 | — |
| Tangible book value per share | −$0.39 | −$0.38 | −$0.16 | −$0.04 | — |
| Capex per share | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Debt per share | $0.05 | $0.05 | — | — | — |
| Shares outstanding | 73.3M | 71.6M | 89.5M | 90.2M | 81.4M |
| Change in shares outstanding | +2.4% | −20.0% | −0.8% | +10.8% | — |
| Returns & profitability | |||||
| Return on equity (ROE) | −54.4% | −59.0% | −41.1% | −30.0% | — |
| Return on invested capital (ROIC) | −39.3% | −43.1% | −31.1% | −21.3% | — |
| Return on assets (ROA) | −26.7% | −32.0% | −28.1% | −25.5% | — |
| Return on tangible assets | −89.9% | −192.8% | −164.2% | −403.9% | — |
| Financial health | |||||
| Total debt | $3.8M | $3.8M | — | — | — |
| Cash & short-term investments | $3.9M | $112 | $26,523 | $289,175 | — |
| Net debt | −$124,797 | $3.8M | −$26,523 | −$289,175 | — |
| Debt / equity | 0.08 | 0.08 | — | — | — |
| Debt / assets | 0.04 | 0.05 | — | — | — |
| Current ratio | 0.56 | 0.34 | 0.37 | 0.46 | — |
| Quick ratio | 0.11 | 0.08 | 0.37 | 0.46 | — |
| Interest coverage | -107.9 | — | — | — | — |
| Working capital | −$21.9M | −$21.7M | −$13.3M | −$3.2M | — |
| Invested capital | $44.7M | $49.9M | $25.5M | $36.0M | — |
| Tangible asset value | −$28.5M | −$27.3M | −$14.5M | −$3.7M | — |
| Net current asset value | −$28.5M | −$27.3M | −$14.5M | −$3.7M | — |
| Graham net-net per share | −$0.56 | −$0.48 | −$0.25 | −$0.07 | — |
| Capital allocation | |||||
| Capex / operating cash flow | — | 0.0% | — | — | — |
| Capex / depreciation | — | — | — | 0.00 | — |
| Efficiency | |||||
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Average payables | $8.5M | $2.5M | $690,678 | $92,311 | — |
| Average inventory | $15.3M | $4.1M | $0 | — | — |
| Intangibles / total assets | 72.7% | 87.0% | 83.8% | 93.7% | — |
Computed from CTOR's annual financial statements (latest annual report filed September 30, 2025) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
CTOR valuation and financial ratios
Citius Oncology earned a return on equity of −54.4% and a return on invested capital of −39.3% in fiscal 2025. It ended the year with $3.8 million of debt and $3.9 million in cash and short-term investments, a net cash position of $0.1 million. The share count fell 10.0% from 81.4M to 73.3M over 4 years.
See the CTOR income statement, the CTOR chart for price history, or the CTOR stock overview for the latest quote and news.
CTOR key metrics FAQ
What is Citius Oncology's return on equity?
Citius Oncology's return on equity (ROE) was −54.4% in fiscal 2025: net income of -$24.8 million on average shareholders' equity of $45.5 million.
What is Citius Oncology's ROIC?
Citius Oncology's return on invested capital was −39.3% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Citius Oncology have?
Citius Oncology had total debt of $3.8 million at the end of fiscal 2025, a debt-to-equity ratio of 0.08 and more cash than debt.
What is Citius Oncology's free cash flow yield?
Citius Oncology generated -$5.5 million of free cash flow in fiscal 2025, a free cash flow yield of −3.7% on its market value at year-end ($148.7 million).
What is Citius Oncology's current ratio?
Citius Oncology's current ratio was 0.56 at the end of fiscal 2025: current assets were 0.56 times current liabilities.